A Study to Evaluate a Single Intravenous Dose of Motavizumab for the Treatment of Children Hospitalized With Respiratory Syncytial Virus (RSV) Illness

NCT00421304 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

118

Enrollment

INDUSTRY

Sponsor class

Conditions

RSV Illness in ≤12 Months of Participants

Interventions

BIOLOGICAL: Motavizumab
OTHER: Placebo

Sponsor

MedImmune LLC